Subscribe for full access
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Recommendation Rating
2
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Mean 0.38
Low: 0.17
High: 0.5
Total Analysts: 3
Company Profile
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing and commercializing radiopharmaceutical products and nuclear medicines for both therapeutic and diagnostic applications in precision oncology. The Company’s subsidiary includes Radiopharm Theranostics (USA) Inc. The Company has a pipeline of four licensed platform technologies, Nano-monoclonal antibodies (mAbs), Pivalate, AVβ6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, RAD201, RAD202, RAD204, RAD205, RAD207, RAD301, RAD302, RAD401 and RAD402.
We do our best to screen stocks as accurately as possible. Please let us know in the Community if you spot an error or find something questionable. Jazaak Allahu khairan.
